Table 3.
Comparing IgG and IgM Borrelia seropositivity to various commercial assays in a patient group with persistent symptoms attributed to Lyme borreliosis to seropositivity in healthy controls.
| PSL N = 40 (%) |
HC N = 40 (%) |
p-Value | ||
|---|---|---|---|---|
| Positive Serion ELISA (%) | IgG | 23 (58) | 2 (5) | <0.05 |
| IgM | 16 (40) | 2 (5) | <0.05 | |
| Positive Euroimmun EUROLINE–WB | IgG | 27 (68) | 3 (8) | <0.05 |
| IgM | 18 (45) | 2 (5) | <0.05 | |
| Positive Euroimmun EUROLINE–RN–AT | IgG | 25 (63) | 5 (13) | <0.05 |
| IgM | 18 (45) | 4 (10) | <0.05 | |
| Positive Mikrogen RecomLine | IgG | 20 (50) | 3 (8) | <0.05 |
| IgM | 14 (35) | 1 (3) | <0.05 | |
| Positive Mikrogen RecomBead | IgG | 19 (48) | 2 (5) | <0.05 |
| IgM | 11 (28) | 0 (0) | <0.05 | |
| Positive Serion Multianalyte system | IgG | 24 (60) | 4 (10) | <0.05 |
| IgM | 14 (35) | 2 (5) | <0.05 |
Data are presented as numbers and percentages. The statistical analysis used was Pearson’s Chi-square test. PSL—patient group with persistent symptoms attributed to Lyme borreliosis; HC—healthy controls.